Results 201 to 210 of about 29,702 (243)
Some of the next articles are maybe not open access.
Abortion Exceptionalism and the Mifepristone REMS.
Contraception, 2021Since its initial approval, mifepristone has been regulated with a strictness out of proportion to its risks. This paper explores how the regulation of mifepristone, specifically the Risk Evaluation and Mitigation Strategies (REMS) requirements, are a ...
J. Serpico
semanticscholar +1 more source
Contraception, 2020
OBJECTIVES The gold standard of medication abortion, mifepristone and misoprostol, became available in Canada in 2017 as a combination pack under the trade name Mifegymiso®.
K. Laroche, A. Foster
semanticscholar +1 more source
OBJECTIVES The gold standard of medication abortion, mifepristone and misoprostol, became available in Canada in 2017 as a combination pack under the trade name Mifegymiso®.
K. Laroche, A. Foster
semanticscholar +1 more source
Journal of Obstetrics and Gynaecology Canada, 2020
OBJECTIVE Abortion-related complications remain one of the leading causes of maternal morbidity and mortality worldwide. Nearly half of all abortions are unsafe, and the vast majority of these occur in low- and middle-income countries.
I. Ferguson, H. Scott
semanticscholar +1 more source
OBJECTIVE Abortion-related complications remain one of the leading causes of maternal morbidity and mortality worldwide. Nearly half of all abortions are unsafe, and the vast majority of these occur in low- and middle-income countries.
I. Ferguson, H. Scott
semanticscholar +1 more source
Contraception, 2020
OBJECTIVE We analyzed trends in medication abortion provision before and after the 2017 introduction of mifepristone in Canada. METHODS We reviewed 2016-2018 abortion services data from Canadian members of the National Abortion Federation (NAF) to ...
A. Yalahow +3 more
semanticscholar +1 more source
OBJECTIVE We analyzed trends in medication abortion provision before and after the 2017 introduction of mifepristone in Canada. METHODS We reviewed 2016-2018 abortion services data from Canadian members of the National Abortion Federation (NAF) to ...
A. Yalahow +3 more
semanticscholar +1 more source
Journal of Obstetrics and Gynaecology Canada, 2020
OBJECTIVE Mifepristone became available in Canada in January 2017, but provincial medical policy delayed its use for medical abortion (MA) in Québec for 1 year.
M. Wagner +7 more
semanticscholar +1 more source
OBJECTIVE Mifepristone became available in Canada in January 2017, but provincial medical policy delayed its use for medical abortion (MA) in Québec for 1 year.
M. Wagner +7 more
semanticscholar +1 more source
Mifepristone: Antineoplastic Studies
Clinical Obstetrics and Gynecology, 1996Emerging research suggests that mifepristone may have significant clinical applications in the treatment of certain neoplastic disorders. For example in vitro studies have shown that RU-486 can inhibit or stimulate--depending on the cell line and the hormonal milieu of the culture medium--the growth of breast cancer cells. In hormone-sensitive breast
O, Sartor, W D, Figg
openaire +2 more sources
Mifepristone polymorph with enhanced solubility, dissolution and oral bioavailability.
Steroids, 2020Mifepristone is one of potent anti-progesterone agents, which binds to progesterone receptors and glucocorticoid receptors. Until now, there are a lot of research focusing on enhancing the solubility and oral bioavailability of Mifepristone.
Juan Xu +5 more
semanticscholar +1 more source